Posted by Michael Wonder on 25 Nov 2021
Tagrisso, Opdivo fail to get broader reimbursement
25 November 2021 - AstraZeneca Korea’s non-small-cell lung cancer treatment Tagrisso (osimertinib) and Ono Pharma Korea’s immunotherapy Opdivo (nivolumab) failed to get expanded health insurance coverage.
On Wednesday, the Health Insurance Review and Assessment Service released the results of the cancer drug assessment committee’s review on anti-cancer drugs.
